Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …

Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and
Other Medical Visits* Page 1 Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related …

Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …

Background The impact of nirmatrelvir/ritonavir treatment on shedding of viable virus in
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Methods A …

Background Information on the effectiveness of nirmatrelvir/ritonavir against the omicron is
limited. The clinical response and viral kinetics to therapy in the real world need to be …

To evaluate the effect of Nirmatrelvir‐ritonavir therapy and coronavirus disease 2019
(COVID‐19) vaccination on clinical outcomes of severe acute respiratory syndrome …

Background: Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult
patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Objective To evaluate the efficacy and safety of Nirmatrelvir/Ritonavir in the treatment of the
Omicron variant of coronavirus disease 2019 (COVID-19). Methods Data from 58 patients …

Prolonged viral shedding may pose a threat to the control of coronavirus disease‐2019
(COVID‐19), and data on the duration of severe acute respiratory syndrome coronavirus 2 …